BlossomHill Therapeutics Earnings Call Transcripts

Fiscal Year 2026

H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill presented strong phase I data for its lead EGFR inhibitor, showing high response rates and durability in C797S-resistant patients, with a favorable safety profile and differentiation from competitors. Key milestones include pivotal trial planning and new data readouts through 2027.

Read full transcript →